BTA biota holdings limited

Well it looks like Bota doesn't want to diversify out of self...

  1. 13,958 Posts.
    lightbulb Created with Sketch. 139
    Well it looks like Bota doesn't want to diversify out of self limiting respiratory diseases. Which means there will always be debate about the cost benefit of shaving 1 day off symptoms of influenza or rhinovirus or RSV.

    There's still debate whether Medimmune's RSV drug is cost effective & efficacious but it didn't stop it earning $1 billion per annum in a small cohort of the population not long ago.

    My 2c.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.